Sprint Bioscience AB (SE:SPRINT)

:SPRINT

SPRINT

Sprint Bioscience AB

RESEARCH TOOLSreports

Want to see SE:SPRINT full AI Analyst Report?

Sprint Bioscience AB (SPRINT) Price & Analysis

1 Followers

SPRINT Stock Chart & Stats

kr1.48

-kr0.03(-2.43%)

At close: Mar 06 4:00 PM EST

kr1.48

-kr0.03(-2.43%)

Day’s Range― - ―

52-Week Rangekr0.36 - kr4.14

Previous CloseN/A

Volume19.16K

Average Volume (3M)560.98K

Market Cap

kr339.76M

Enterprise Valuekr213.06M

Total Cash (Recent Filing)kr126.70M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)1.5

Beta1.49

Next Earnings

May 13, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)1.07

Shares Outstanding105,515,540

10 Day Avg. Volume1,502,692

30 Day Avg. Volume560,983

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)1.14

Price to Sales (P/S)0.81

P/FCF Ratio1.63

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)kr80.50M

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA debt-free balance sheet materially lowers refinancing and interest-rate risk and preserves financial flexibility. Over a multi-month horizon this supports funding of discovery work, enables selective out-licensing negotiations, and reduces the probability of forced dilutive financing.

2025 Revenue & Profitability InflectionThe clear step-change to materially higher revenue and positive net income in 2025 indicates improved commercial or milestone capture and operating leverage. This provides a stronger earnings base that can support reinvestment, partner confidence, and more predictable program funding.

Capital-efficient Partnering ModelA partnering/out-licensing model lets Sprint focus on early discovery while leveraging partner capital for costly clinical stages. Structurally this lowers capital intensity, accelerates program throughput per R&D dollar, and creates milestone and royalty upside without funding full development alone.

Bears Say

Volatile Results And Cash FlowsHistoric swings between losses and strong profits reduce earnings predictability and complicate multi-month planning. Volatility stems from timing of license/milestone receipts and uneven operating cash conversion, raising forecasting risk for partners and investors.

Dependence On Partnership TimingRevenue and cash generation are highly dependent on when partners pay upfront, milestones, or reimburse research. This structural lumpiness can delay revenue recognition, force interim funding, and limit the company's ability to smoothly scale operations or commit to long lead expenditures.

Historical Low Equity / Funding SensitivityA history of a very low equity base signals prior funding sensitivity and potential future dilution risk. If milestone timing slips or cash generation falters, the company may need external capital, which can dilute shareholders and constrain strategic optionality during critical program phases.

SPRINT FAQ

What was Sprint Bioscience AB’s price range in the past 12 months?

Sprint Bioscience AB lowest stock price was kr0.36 and its highest was kr4.14 in the past 12 months.

What is Sprint Bioscience AB’s market cap?

Sprint Bioscience AB’s market cap is kr339.76M.

When is Sprint Bioscience AB’s upcoming earnings report date?

Sprint Bioscience AB’s upcoming earnings report date is May 13, 2026 which is in 13 days.

How were Sprint Bioscience AB’s earnings last quarter?

Sprint Bioscience AB released its earnings results on Feb 11, 2026. The company reported kr1.073 earnings per share for the quarter, beating the consensus estimate of N/A by kr1.073.

Is Sprint Bioscience AB overvalued?

According to Wall Street analysts Sprint Bioscience AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Sprint Bioscience AB pay dividends?

Sprint Bioscience AB does not currently pay dividends.

What is Sprint Bioscience AB’s EPS estimate?

Sprint Bioscience AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sprint Bioscience AB have?

Sprint Bioscience AB has 105,515,540 shares outstanding.

What happened to Sprint Bioscience AB’s price movement after its last earnings report?

Sprint Bioscience AB reported an EPS of kr1.073 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -9.091%.

Which hedge fund is a major shareholder of Sprint Bioscience AB?

Currently, no hedge funds are holding shares in SE:SPRINT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sprint Bioscience AB

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.